Condition:  Advanced Ovarian Cancer
Interventions:  Drug: Bevacizumab;  Drug: Durvalumab;  Drug: Olaparib;  Drug: Placebo olaparib;  Drug: Durvalumab placebo;  Drug: Carboplatin+Paclitaxel
Sponsors:  AstraZeneca;  European Network of Gynaecological Oncological Trial Groups (ENGOT);  GOG Foundation, Inc. (GOG Foundation);  Myriad Genetic Laboratories, Inc.
**RECRUITING NOW**
Interventions:  Drug: Bevacizumab;  Drug: Durvalumab;  Drug: Olaparib;  Drug: Placebo olaparib;  Drug: Durvalumab placebo;  Drug: Carboplatin+Paclitaxel
Sponsors:  AstraZeneca;  European Network of Gynaecological Oncological Trial Groups (ENGOT);  GOG Foundation, Inc. (GOG Foundation);  Myriad Genetic Laboratories, Inc.
**RECRUITING NOW**
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
